Thomas Barnard
Contributor since: 2009
Company: Business Risk Management, Inc.
Articles
Generex: Establishing A Value For Antigen Express' Dividend Shares
A Planned Spinoff Of Cancer Vaccines At Generex
The New Generex: Unlocking The Value
Tax Cuts, Hurricanes, Fires And A Good Jobs Report = Correction
What Would I Like In My Market Top Algorithm?
This Market Top Is A Strange Animal
CounterPath Contract Leverage (My Best Idea)
Nightmare For 401(K)ers: Assets May Go Down By 50%
Regression To The Mean
This Past Week In Telephone
It's A Good Time To Be A Consumer
With Ebola Looming, When Will The Defense Department Get Around To Generex?
From 1930 To 1995, The P/E Peak Was 24 In January 1966
Generex: A Stock Suitable Only For Its Officers And Directors Or Carl Icahn
Acquisition Target: CounterPath Corp.
Ben Bernanke Owns This Bubble, Baby
BlackBerry 10 And The Battle Of The Network Mobile Operating Systems
Generex: Research For Sale On The Cheap
No Hedge Funds Inside Banks
AT&T And Verizon Are Progressing In Transformation To Data Transmission Utilities
Remember When Cisco Had A Market Cap Of $500 Billion? What About Apple?
The Impact of Technology: Unemployment May Be More Stubborn This Time
Facebook Is to LinkedIn as Skype Is to Counterpath Corp.
Facebook Goes Asocial
Research In Motion Needs to Circle Back to the Enterprise
Why Major Telecoms Are in Trouble
Microsoft and Skype: The Take Away
Microsoft: Overview of a Possible Also-Ran
Generex: Do Development Drug Companies Have No Value?
News Next Week for Generex May Reduce Need for Reverse Split
Generex: Reverse Split Not Approved
Generex Brouhaha: Big Pharma Is Actually Not So Smart